Coagulopathy and hemostasis management in patients undergoing liver transplantation: Defining a dynamic spectrum across phases of care

Anjana A. Pillai, Michael Kriss, David P. Al‐Adra, Ryan M. Chadha, Melissa M. Cushing, Khashayar Farsad, Brett E. Fortune, Aaron S. Hess, Robert Lewandowski, Mitra K. Nadim, Trevor Nydam, Pratima Sharma, Constantine J. Karvellas, Nicolas Intagliata – 6 March 2022 – Patients with acute and chronic liver disease present with a wide range of disease states and severity that may require liver transplantation (LT). Physiologic alterations occur that are dynamic throughout all phases of perioperative care, creating complex management scenarios that necessitate multidisciplinary clinical care.

Emerging immunotherapy for HCC: A guide for hepatologists

Friedrich Foerster, Simon Johannes Gairing, Sumera Irie Ilyas, Peter Robert Galle – 6 March 2022 – HCC is one of the most common cancers worldwide, and the third leading cause of cancer‐related death globally. HCC comprises nearly 90% of all cases of primary liver cancer. Approximately half of all patients with HCC receive systemic therapy during their disease course, particularly in the advanced stages of disease.

Sinusoidal obstruction syndrome after liver transplantation: A multicenter observational study

Aránzazu Caballero‐Marcos, Isabel Peligros, Judith Pérez‐Rojas, Isabel Campos‐Varela, Jordi Colmenero, Miguel Ángel Gómez‐Bravo, Iago Justo, Alejandra Otero, Esther Molina‐Pérez, Luisa González‐Diéguez, Carme Baliellas, Mario Romero‐Cristobal, Victoria Aguilera, Lluís Castells, Alba Díaz, Luis Miguel Marín‐Gómez, Carmelo Loinaz, Rafael Bañares, Magdalena Salcedo – 6 March 2022

Incidence of acute rejection and patient survival in combined heart–liver transplantation

Kai Zhao, Roy Wang, Malek Kamoun, Lauren Callans, Remy Bremner, Eduardo Rame, Rhondalyn McLean, Marisa Cevasco, Kim M. Olthoff, Matthew H. Levine, Abraham Shaked, Peter L. Abt – 4 March 2022 – Combined heart–liver transplantation (CHLT) is indicated for patients with concomitant end‐stage heart and liver disease or patients with amyloid heart disease where liver transplantation mitigates progression. Limited data suggest that the liver allograft provides immunoprotection for heart and kidney allografts in combined transplantation from the same donor.

Activated and nonactivated MSCs increase survival in humanized mice after acute liver injury through alcohol binging

Juan Carlos Hernandez, Da‐Wei Yeh, Joel Marh, Hye Yeon Choi, Julia Kim, Shefali Chopra, Li Ding, Matthew Thornton, Brendan Grubbs, Leonard Makowka, Linda Sher, Keigo Machida – 4 March 2022 – The ability of the liver to regenerate after injury makes it an ideal organ to study for potential therapeutic interventions. Mesenchymal stem cells (MSCs) possess self‐renewal and differentiation properties, as well as anti‐inflammatory properties that make them an ideal candidate for therapy of acute liver injury.

Associations of sarcopenia with graft failure and mortality in patients undergoing living donor liver transplantation

Ji‐Hoon Sim, Hye‐Mee Kwon, Kyung‐Won Kim, You‐Sun Ko, In‐Gu Jun, Sung‐Hoon Kim, Kyoung‐Sun Kim, Young‐Jin Moon, Jun‐Gol Song, Gyu‐Sam Hwang – 3 March 2022 – Recent studies have reported that sarcopenia influences morbidity and mortality in surgical patients. However, few studies have investigated the associations of sarcopenia with short‐term and long‐term graft failure in recipients after living donor liver transplantation (LDLT). In this study, we investigated the associations between sarcopenia and graft failure/mortality in patients undergoing LDLT.

Subscribe to